Weight Loss Drugs 2026: Brands, Results, Disability
Obesity care in the United States has been rewritten in less than a decade. The pharmacological treatment of obesity used to mean phentermine prescriptions and over-the-counter orlistat at the drugstore, with modest results that often vanished the moment a patient stopped taking the pill. That world still exists, but it now sits alongside a generation of injectable and oral medications that routinely produce double-digit percentage weight loss and are reshaping how physicians, insurers, and courts think about body weight itself (Obesity Medicine Association, 2026).
As of April 2026, the U.S. Food and Drug Administration has approved nine pharmacological options for long-term or short-term weight management in adults, along with one medical device classified as a prescription product and a single over-the-counter option. Two of those medications arrived within the last five months: the oral formulation of Wegovy in December 2025 and Foundayo (orforglipron) on April 1, 2026 (U.S. Food and Drug Administration, 2026a). A higher-dose injectable version of Wegovy, branded Wegovy HD, was approved on March 19, 2026 (U.S. Food and Drug Administration, 2026b). The pipeline behind these products is crowded. Analysts at Ozmosi have identified roughly three dozen GLP-1-related weight management candidates in development, with new launches expected every year for the foreseeable future.
How These Medications Actually Work
Most of the newer weight loss drugs belong to a class called incretin mimetics. They imitate hormones the gut releases after meals – glucagon-like peptide-1 (GLP-1) and, in some cases, glucose-dependent insulinotropic polypeptide (GIP). These hormones slow gastric emptying, blunt appetite signals in the brain, and improve insulin sensitivity. The older medications work differently: some are stimulants that suppress appetite (phentermine), some block fat absorption in the intestine (orlistat), and some combine neuromodulators that reduce reward-driven eating (Contrave).
The practical distinction that matters most to patients is simpler than the pharmacology. Some of these products are injected under the skin, usually once a week. Others are swallowed. Some require a prescription and physician supervision. Only one true anti-obesity drug is sold without a prescription in the United States.
Injectable Prescription Medications
Wegovy (semaglutide)
Manufactured by Novo Nordisk and approved in 2021 for chronic weight management, Wegovy delivers semaglutide once weekly by subcutaneous injection using a pre-filled pen. Phase 3 trials reported mean weight reduction of roughly 14.9% of body weight over 68 weeks at the 2.4 mg dose. The drug is approved for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related comorbid condition, and for adolescents 12 and older with a BMI at or above the 95th percentile. In March 2026 the FDA approved a higher 7.2 mg dose called Wegovy HD, which produced additional weight reduction beyond the standard dose in clinical testing (U.S. Food and Drug Administration, 2026b).
Zepbound (tirzepatide)
Eli Lilly’s Zepbound, approved for obesity in late 2023, is currently the most effective weight loss medication on the U.S. market. It is a dual GLP-1 and GIP receptor agonist administered once weekly by injection. In the head-to-head SURMOUNT-5 trial published in The New England Journal of Medicine, tirzepatide produced a mean weight reduction of 20.2% at 72 weeks compared with 13.7% for semaglutide, the first direct clinical comparison of the two (Aronne et al., 2025). A separate phase 3 trial in participants with knee osteoarthritis and obesity found weight losses of up to 28.7% with the related triple-agonist retatrutide, which remains in development but signals where this class is heading.
Saxenda (liraglutide)
Liraglutide, marketed by Novo Nordisk as Saxenda, was the first GLP-1 receptor agonist approved for weight management in adults and is also approved for adolescents 12 and older. Unlike Wegovy and Zepbound, it must be injected daily rather than weekly. Its weight loss effect is more modest, typically 5% to 8% of body weight at 56 weeks, but it remains relevant for patients who cannot tolerate the newer agents or whose insurance favors it on formulary.
Oral Prescription Medications
Wegovy Pill (oral semaglutide for obesity)
In December 2025 the FDA approved an oral formulation of Wegovy, the first oral GLP-1 receptor agonist cleared specifically for chronic weight management. At the highest dose, trial participants lost an average of 16.6% of their body weight after 64 weeks, and roughly one in three lost at least 20% (AARP, 2026). The pill is taken once daily on an empty stomach with a small amount of water, a protocol some patients find inconvenient. A lower-dose oral semaglutide product called Rybelsus has been available since 2019 for type 2 diabetes and is sometimes prescribed off label.
Foundayo (orforglipron)
Approved on April 1, 2026, Foundayo is Eli Lilly’s oral GLP-1 receptor partial agonist and the only weight loss pill of its class that can be taken any time of day without food or water restrictions. Its chemistry – a small-molecule nonpeptide rather than a peptide – makes it more stable in the stomach. In the ATTAIN-1 trial, adults taking the highest dose of 36 mg lost an average of 12.4% of body weight, about 27 pounds, after 72 weeks, compared with about 2 pounds for placebo (Eli Lilly and Company, 2026). Foundayo was the first new molecular entity approved under the FDA’s Commissioner’s National Priority Voucher program, which shortened the review timeline by several months (U.S. Food and Drug Administration, 2026a).
Qsymia (phentermine and topiramate)
Qsymia combines a controlled-substance appetite suppressant (phentermine) with the anticonvulsant topiramate in an extended-release capsule. It is approved for chronic weight management in adults and in pediatric patients 12 and older. Mean weight loss in trials runs about 8% to 10% at one year. It requires prescriber enrollment in a Risk Evaluation and Mitigation Strategy because of the teratogenic potential of topiramate.
Contrave (naltrexone and bupropion)
Contrave pairs a low-dose opioid antagonist with an antidepressant to reduce appetite and cravings. It produces roughly 5% to 6% mean weight loss at one year. The combination can raise blood pressure and is contraindicated in patients taking opioids, so clinician selection matters.
Phentermine (Adipex-P, Lomaira)
Phentermine is the oldest and cheapest prescription weight loss medication still in wide use, originally approved in 1959. It is a sympathomimetic amine sold as Adipex-P, Lomaira, and under its generic name. It is FDA approved only for short-term use, generally up to 12 weeks, because of its stimulant profile and potential for tolerance. Many clinicians prescribe it in cycles or alongside topiramate. It remains popular in part because generic monthly costs can fall below $15 without insurance.
Xenical (prescription orlistat)
Orlistat, marketed at the 120 mg prescription strength as Xenical, inhibits pancreatic lipase and blocks absorption of about 30% of dietary fat. Average weight loss is 3% to 5% at one year. Its gastrointestinal side effects – oily stools, flatulence, fecal urgency when patients eat high-fat meals – are well known and are the reason many patients discontinue it.
